Prophylactic therapeutics for bleeding and thrombotic disorders
Founders
Johan Henrik Faber(Denmark · ♂)— After 12 years at Novo Nordisk leading research technologies, he co-founded Hemab (and was its first CEO) to develop preventative therapies for rare bleeding disorders.
Søren Bjørn(Denmark · ♂)— A Novo Nordisk colleague of Faber, he co-founded Hemab to pioneer antibody-based treatments for bleeding and thrombotic disorders.
Hans Wandall(Denmark · ♂)— Co-founded Hemab drawing on coagulation expertise to develop next-generation bleeding-disorder therapeutics.
Thomas Batchelor(♂)— Co-founded Hemab to advance prophylactic treatments for underserved bleeding and thrombotic disorders.
Mads Behrndt(Denmark · ♂)— Co-founded Hemab to build a pipeline of monoclonal and bispecific antibody therapeutics for rare blood disorders.
Team & hubs
In the network
Shares the most investors with (number = shared investors):